Cell-Free DNA's Role in Geriatric Syndromes

pic of pac man eating dots
Published in Aging Matters - Winter 2026

Lolita Nidadavolu remembers her origin story as a researcher clearly: the moment she saw a 2006 Nature cover featuring scientist Paul W.K. Rothmund’s DNA smiley face — literally a two-dimensional smiley face built of nano DNA and colored yellow. “This article was talking about how we can utilize DNA to be a scaffolding structure to make DNA origami,” she says. “Every once in a while, I think about that article because it reminds me how cool it is thinking about new applications of existing things that we know can help provide solutions to questions that may not yet have been asked.”

female doctorLolita Nidadavolu, M.D., Ph.D.

This fascination with discovery has fueled Nidadavolu’s career. While majoring in chemistry as an undergraduate at Johns Hopkins University, she was drawn to biomedical research, specifically developing new treatments for patients. Through years of study at a postbaccalaureate program at the NIH, medical training at the University of Pittsburgh and Brown University, and a return to Johns Hopkins for a fellowship in geriatric medicine and T32 training in translational aging research, she refined her focus. She says, “The lab that I was in [in graduate school] was studying microRNAs and how they can influence disease development. My project was on how microRNAs can make cellular changes that contribute to aging in a mouse model of rapid aging (progeria). I was a graduate student learning about aging biology at a time when there were a lot of huge discoveries coming out. I wanted to be a part of that, and I knew I wanted to be a geriatrician and have this clinical keystone to the research I was doing.”

From Bench to Bedside

As a field, aging research has obviously evolved since that 2006 article. As the population of the United States is aging, the desire to know more about the processes and mechanisms of growing older has increased. Researchers are studying what causes aging from multiple angles, determined to improve individuals’ healthspan. “We have the potential now to have more of a nuanced approach to really understand what’s happening,” Nidadavolu says, “and to be able to personalize treatments [for patients].”

“When our body’s cells are turning over, our body has mechanisms – kind of like a Pac-Man of sorts – to eat the extra proteins or DNA fragments.”

— Lolita Nidadavolu

Bringing her research results to the bedside of those patients is deeply important to Nidadavolu, now an Armstrong Foundation Center for Innovative Medicine Human Aging Project Scholar. She currently works with older adults with dementia in the Memory Clinic, but also spends some time on the inpatient service at Johns Hopkins Bayview Medical Center. With the support and guidance of mentors Peter Abadir and Esther Oh, she’s hit her stride, looking at inflammatory responses and their impact on geriatric syndromes like frailty and dementia while continuing to help and care for her patients longterm. She says, “It’s been a good opportunity to talk to my patients, see what their thoughts are on the research I’m doing, and talk about what they hope to see out of it.” Some of her patients have been curious enough in these conversations to join her studies, and she appreciates the collegiality of Johns Hopkins that has encouraged collaboration and forward-thinking work.

Like Pac-Man Eating DNA Fragments

Starting from her time as a postdoc, Nidadavolu has researched circulating cell-free DNA. “When our body’s cells are turning over, our body has mechanisms — kind of like a Pac-Man of sorts — to eat the extra proteins or DNA fragments,” she says, “But it’s an inefficient system, and there’s some thought that as we get older, especially when it comes to degrading DNA, it may become even less efficient.” This can lead to more DNA in the bloodstream, which increases inflammation and can lead to a variety of problems. “We’ve done a lot of work showing that having higher levels of these DNA fragments in the bloodstream can be associated with different clinical conditions, like developing frailty, dementia and cardiovascular disease. But what is it about these fragments being increased [that causes the conditions]?” Nidadavolu’s lab has found that when a person’s body is facing this sort of increase, the innate immune system response is to attack the DNA. The problem is that often that response has no specific stopping point, which could lead to the person developing other issues triggered by that attack.

“What we know is, these fragments, they’re only looking at one small sliver of the overall system someone has,” she says. “I don’t think this is a switch for someone to develop dementia or any other chronic disorder. What we’re learning more is that, especially as we age, it may not be one contributor that’s causing someone to have a certain medical condition.” She cites the example of bladder issues, which are often the result of multiple things from muscle weakness in the bladder itself to medications that have diuretic side effects to mobility problems. “We learn as geriatrics fellows that there can be many small things that have a bigger impact on quality of life,” she says. “Similarly, there can be many small pathway changes, molecular changes, protein function changes that can lead to diseases developing or age-related changes.”

Nidadavolu’s hope is that eventually her cell-free DNA research can be used to build treatments for people by finding ways to remove the problematic fragments from their blood as a piece of their treatment. That outcome would be further down the road, once she and other researchers know more about how exactly this cell-free DNA ties to dementia, frailty and other conditions. “It’s one piece among all these other pieces,” she says, “and then you figure out where it fits in, and then, based on that, decide what the bedside intervention would be.”